<DOC>
	<DOCNO>NCT00402025</DOCNO>
	<brief_summary>The purpose study assess safety injection talimogene laherparepvec patient pancreatic cancer remove surgery . The study also test whether injection effective treat tumor .</brief_summary>
	<brief_title>Talimogene Laherparepvec Patients With Unresectable Pancreatic Cancer</brief_title>
	<detailed_description>Talimogene laherparepvec conditionally replication competent herpes simplex type-1 virus design use solid tumor . It specifically modify replicate tumor provide local source immune-stimulating cytokine , granulocyte macrophage colony stimulate factor ( GM-CSF ) . It inject directly cancer tumor believe destroy tumor cell direct infection tumor cell enhance immune response due release tumor antigens GM-CSF expression . This open-label , dose-escalation study evaluate safety efficacy talimogene laherparepvec administer direct injection pancreatic tumor use endoscopic ultrasound ( EUS ) -guided fine needle injection ( FNI ) . Only 1 tumor mass within body tail pancreas inject participant . The protocol call evaluation 4 dosing regimen sequential cohort participant ; however , cohort 4 opened enrollment .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<criteria>cytological histological proof adenocarcinoma pancreas unresectable , locally advanced disease ( isolated liver metastasis permit ) tumor least 1 cm diameter screen measurable disease use Response Evaluation Criteria In Solid Tumors ( RECIST ) criteria failure either standard therapy , OR one following : alternative therapeutic high curative potential available ; investigator determination patient could tolerate alternative therapeutic due unacceptable toxicity ; , patient refusal treat available alternative therapeutic age &gt; 18 year life expectancy &gt; 3 month adequate bone marrow function indicate : White blood cell ( WBC ) ≥ 3.0 x 10^9/L platelet ≥ 100 x 10^9/L hemoglobin ≥ 8.5 gm/dL adequate liver function indicate : bilirubin &lt; 1.5 x upper limit normal ( ULN ) alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &lt; 5 x ULN case presence liver metastasis ALT AST &lt; 2.5 x ULN case absence liver metastasis adequate renal function indicate serum creatinine level &lt; 1.5 x ULN . adequate hemostasis indicate international normalized ratio ( INR ) ≤ 1.5 mentally , physically geographically able undergo treatment followup provide write informed consent first patient cohort : seropositive herpes simplex virus type 1 ( HSV1 ) history malignancy within two year prior screen , except prostate cancer ( T1c , T2ab definitive treatment , prostatespecific antigen ( PSA ) &lt; 1 ng/ml , without ongoing hormone suppression ) adequately treat situ carcinoma cervix , basal cell carcinoma , squamous cell carcinoma skin cystic form pancreatic cancer ; microcystic disease may eligible upon discussion Medical Monitor Common Terminology Criteria Adverse Events ( CTCAE ) version 3 grade 2 great clinical pancreatitis within 8 week prior dose OncoVEX^GMCSF metastasis limit liver , image evidence metastatic disease organ tissue serious concomitant systemic disorder would compromise safety patient , discretion investigator evidence compromise immune function include limited : clinically significant absolute lymphocyte count &lt; Lower Limit Normal ( LLN ) know human immunodeficiency virus ( HIV ) , acute chronic active hepatitis B , hepatitis C infection ; concurrently take HIV antiviral medication ( e.g . protease inhibitor , azidothymidine , etc . ) receive intravenous ( IV ) , intramuscular ( IM ) subcutaneous ( SC ) human gamma globulin within 6 month prior dose OncoVEX^GMCSF patient take immunosuppressive agent ( e.g . cyclosporine , tacrolimus , oral systemic corticosteroid dose &gt; 10 mg/day prednisone equivalent ) . pregnancy , lactation lack effective contraception woman childbearing potential ( e.g. , post menopausal &gt; 2 year , tubal ligation ) ; lack effective contraception men partner childbearing potential ; woman must practice effective contraceptive method least three month prior entry trial ( hormonal contraception intrauterine device conjunction barrier method ) ; men must use condom surgically sterilize patient active bacterial viral infection require treatment systemic antibiotic antiviral agent within 2 week prior first dose OncoVEX^GMCSF ) ; ( note : patient active cold sore HSV1 infection must wait lesion crust receive OncoVEX^GMCSF ) surgery require general spinal anesthesia within four week prior dose OncoVEX^GMCSF Treatment investigational agent within 4 week prior first dose OncoVEX^GMCSF serum carbohydrate antigen ( CA ) 19.9 level &gt; 3000 U/mL screen evidence ascites screen abdominal compute tomography ( CT ) scan</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Metastatic</keyword>
	<keyword>Pancreas</keyword>
	<keyword>Adenocarcinoma</keyword>
</DOC>